Commonwealth Scientific and Industrial Research Organisation v Urrbrae Foods Pty Ltd

Commonwealth Scientific and Industrial Research Organisation v Urrbrae Foods Pty Ltd [2025] FCA 1591 is a Federal Court patent support case about a patent application for high amylose wheat. A delegate of the Commissioner of Patents had upheld an opposition on the basis that the claims were broader than the technical contribution disclosed in the specification, particularly because the specification did not show a clear basis for achieving the claimed phenotype across all wheat genetic backgrounds covered by the claims.

Beach J allowed the appeal, set aside the delegate's decision and ordered that the patent application proceed to grant. The Court accepted additional expert evidence from Professor Peter Sharp that the breeding and selection program described in the patent application could produce the claimed phenotype in any variety of bread wheat, including EGA Hume. The judgment is important because it shows both sides of patent support disputes. Broad claims are not automatically invalid just because every embodiment has not been tested, but the applicant must still be able to show that the specification and accepted evidence fairly support the full width of the monopoly claimed. The case also highlights the procedural importance of a de novo appeal, where the Court can consider fresh evidence and reach its own conclusion on validity grounds raised in opposition.

CSIRO filed Australian patent application no 2017292900, titled High Amylose wheat - III. The application had a priority date of 5 July 2016 and concerned wheat grain of the species Triticum aestivum that is hexaploid and has mutations in each of the three SSIIa genes on the A, B and D genomes. The judgment describes these as triple-null mutations. The claimed invention concerned wheat grain with high amylose starch content and a high ratio of amylose to amylopectin.

Urrbrae Foods opposed the grant of the patent. A number of grounds were originally raised, including entitlement, manner of manufacture, novelty, inventive step, utility and support. At the delegate hearing, the grounds pressed were manner of manufacture, entitlement and support under s 40(3) of the Patents Act 1990 (Cth). The delegate upheld the opposition only on support.

The commercial dispute was really about breadth. CSIRO wanted claims that were not confined to one wheat variety. Urrbrae Foods argued that the specification did not justify that breadth. The delegate focused on the examples in the specification, including Example 4, and concluded that while the specification showed particularly favourable results in the Sunco line and some success in the Westonia line, it did not show production within the claim scope in the EGA Hume line. In the delegate's view, the specification did not provide a guiding principle explaining why the claimed phenotype should be expected across other genetic backgrounds.

CSIRO then appealed to the Federal Court under s 60(4). Urrbrae Foods filed a notice submitting to any order the Court might make on the appeal save as to costs. The Commissioner of Patents was granted leave to appear, but later declined to take any active part. That left the Court to determine the matter on the evidence before it, including additional evidence filed by CSIRO.

The central legal issue was support under s 40(3). The Court said that support requires more than the mere mention of claim features in the specification. The description must be the base that fairly entitles the patentee to a monopoly of the width claimed. The judgment also states that, following the Raising the Bar amendments, Australian law on support was intended to align with the law of the United Kingdom and Europe.

Beach J summarised the relevant principles in practical terms. The claims must correspond to and be supported by the technical contribution to the art. The specification must support and enable the skilled person to perform the invention across the whole relevant range of the claims without invention or undue burden. For a product claim, the technical contribution to the art is the ability of the skilled person to make the product.

The Court referred to the familiar warning from Biogen that a patent may exceed the technical contribution to the art if it claims a wide class of products while enabling only one of them and disclosing no principle that would enable the others to be made. But the Court also referred to the idea of a principle of general application. A patentee does not need to test every embodiment. If it is reasonably likely that the disclosed approach will work across the general class claimed, broad claims may still be supported.

So the real question was whether CSIRO's specification, read with the common general knowledge and the evidence accepted by the Court, enabled the skilled person to make the claimed high amylose wheat grain across the breadth of the claims, or whether the claims were broader than what the specification truly put at the skilled person's disposal.

A major feature of the case was procedural. Beach J emphasised that this was not an appeal in the strict sense. It was a hearing de novo in the original jurisdiction of the Court. That means the Court considered the matter afresh on the grounds advanced and the evidence adduced before it. Findings made by the delegate could be taken into account, especially given the delegate's technical expertise, but they did not control the outcome.

That mattered because the Court gave CSIRO leave to adduce additional evidence that had not been before the delegate. CSIRO relied on an affidavit from Professor Peter Sharp affirmed on 14 November 2025. Professor Sharp explained that, by undertaking the breeding and selection program described in the patent application, he considered he could produce grain with the claimed phenotype in any variety of bread wheat, including EGA Hume. He also explained that the failure to do so in Example 4 likely related to the small scale of that experiment.

Beach J accepted that evidence. The judgment expressly states that, given this evidence, the claims of the patent application were supported across their scope. The Court also noted that the delegate had not had the benefit of that evidence and that, through no fault of the delegate, its absence had contributed to the approach taken below.

The judgment also discusses onus. In patent opposition proceedings, the opponent bears the onus of establishing the relevant ground. Beach J noted that where the opponent or the Commissioner has not adduced evidence capable of discharging that onus, some cases have allowed the application to proceed on that basis alone. Here, however, after reviewing the delegate's analysis, the Court encouraged CSIRO to file evidence and then decided the matter on that fuller record.

Beach J allowed the appeal. The Court set aside the delegate's decision of 14 April 2025 and ordered that Australian patent application no 2017292900 proceed to grant. There was no order as to costs.

The key reasoning clearly stated in the judgment is that Professor Sharp's evidence was accepted and that, on that basis, the claims were supported across their scope. The Court accepted his opinion that the breeding and selection program described in the patent application could produce grain with the claimed phenotype in any variety of bread wheat, including EGA Hume. The Court also accepted his explanation that the failure in Example 4 likely reflected the small scale of that experiment.

The judgment contrasts the appeal record with the record before the delegate. The delegate had been concerned that the specification showed success in Sunco and some success in Westonia, but no demonstrated production within the claim scope in EGA Hume, and no guiding principle showing why success should be expected across other genetic backgrounds. On the appeal evidence, however, the Court considered that the patent application provided a proof of principle such that it would appear reasonably likely to the skilled person that the claimed grain could be made in a range of different genetic backgrounds, including EGA Hume.

The Court also distinguished the situation from cases where a claim fails because the skilled person is left to undertake uncertain trial and error. On the accepted evidence here, the breeding and selection program was not merely an invitation to conduct an open-ended research project. It was a disclosed approach that could support the breadth of the claims.

This case is especially relevant for businesses that file patent applications before every variant of a product has been physically made or tested. That is common in agritech, biotech, medtech, advanced manufacturing and software-enabled technical products. The judgment confirms that broad claims are not automatically invalid just because every embodiment has not been demonstrated. But the applicant must still be able to show that the specification, together with common general knowledge and, if necessary, evidence, supports the full width of the claim.

For business owners, the practical risk is straightforward. If your examples only show one or two successful embodiments, an opponent may argue that your claims overreach. The attack will be stronger if the specification itself suggests that background conditions, materials, strains or variants matter, but does not explain why the invention should still work across the broader class claimed. In that situation, the dispute may turn on whether there is a genuine principle of general application or just a hope that more testing will eventually produce more successful examples.

The case also shows the importance of evidence strategy. CSIRO succeeded after filing additional expert evidence on appeal. That does not mean businesses should rely on fixing support problems later. Opposition and appeal proceedings are expensive and uncertain. A better approach is to work with patent counsel and technical staff before filing to identify what the invention really teaches, what breadth can honestly be defended, and what fallback positions should be included.

It is also worth noting the commercial timing point. Pending patent rights can be central to fundraising, licensing and collaboration discussions, but they remain vulnerable before grant. If a broad claim is challenged and the specification does not clearly support it, the value of the application can change quickly. Businesses should therefore treat patent drafting as part of commercial risk management, not just a filing exercise.

Several features of the record shaped the outcome. First, the patent application itself mattered because the delegate and the Court both focused on what the specification disclosed about different wheat lines, especially Sunco, Westonia and EGA Hume. Second, Example 4 became important because it was used to argue that the claimed phenotype had not been shown in EGA Hume.

Third, the conduct of the parties on appeal mattered. Urrbrae Foods submitted to any order the Court might make save as to costs. The Commissioner of Patents was initially given leave to appear but later declined to take an active role. The Court noted that, in those circumstances, the patent application stood effectively unchallenged unless evidence was filed that addressed the support issue. Rather than deciding the matter on that basis alone, the Court encouraged CSIRO to file evidence.

Fourth, Professor Sharp's affidavit was decisive on the reasoning clearly stated in the judgment. It directly addressed the practical question that had troubled the delegate: whether the breeding and selection program described in the patent application could produce the claimed phenotype across the breadth of the claims, including in EGA Hume. Once that evidence was accepted, the support objection failed.

Does support mean you must test every embodiment before filing? No. The judgment makes clear that a patentee does not need to prove every embodiment has been tried and tested. What matters is whether the specification discloses a principle of general application and whether it would appear reasonably likely to the skilled person that the invention will work across the claim range.

What is the danger of relying on one successful example? A single successful example may not justify a broad monopoly if the specification does not explain why the same result should be expected across other variants. That was the concern at delegate level, where the specification was said to show stronger results in some wheat lines than others without a sufficient guiding principle.

Why did the appeal process matter so much here? Because the Federal Court heard the matter de novo. That allowed CSIRO to rely on additional expert evidence that had not been before the delegate. The accepted evidence directly addressed the gap identified below.

Can a business assume it can fix support problems later with expert evidence? No. This case shows that later evidence can matter, but it does not remove the commercial risk of a weak filing position. Opposition and appeal proceedings are costly and uncertain, so businesses should still aim to file with a specification that genuinely supports the intended claim breadth.

What is the practical drafting point? If you want claims that extend across multiple varieties, materials or technical settings, the specification should explain why the invention is expected to work across that range. If the invention depends on a breeding program, manufacturing pathway or technical method, the disclosure should show more than a hope that further work might eventually succeed.

The patent application had a priority date of 5 July 2016. The delegate's decision upholding the opposition on support was given on 14 April 2025. Urrbrae Foods filed its notice submitting to any order save as to costs on 23 July 2025. The Federal Court heard the matter on 29 August and 5 December 2025. Beach J delivered judgment and orders on 16 December 2025, allowing the appeal and ordering that the application proceed to grant.

The judgment clearly records the final orders. This page should be read as a case explainer, not as advice on the validity of any other patent or application.

This page summarises Commonwealth Scientific and Industrial Research Organisation v Urrbrae Foods Pty Ltd [2025] FCA 1591 in the Federal Court of Australia. The published reasons available here are truncated near the end, but the orders, procedural posture, legal framework and the Court's acceptance of Professor Sharp's evidence are clearly stated.

The summary focuses on those clearly stated parts of the judgment. If you are assessing a live patent strategy, opposition or drafting issue, obtain advice on the full decision and your own technical facts.